AstraZeneca antibody cocktail slashes risk of symptomatic COVID-19, setting up regulatory filings and a lifeline for the immunosuppressed

AstraZeneca has caught a break. After enduring a series of struggles in COVID-19, the drugmaker has shown its long-acting antibody cocktail cuts the risk of symptomatic coronavirus infection by 77%, boosting its effort to provide protection to people underserved by vaccines.